Smith Christopher M
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
PACB Pushes HiFi Sequencing for Clinical Growth. Pacific Biosciences is focusing on its HiFi sequencing technology to drive clinical adoption and achieve $40 million in savings. This strategic push aims to address the company's ongoing profitability challenges while targeting long-term growth. The stock recently saw a volume spike and touched its 200-day moving average, reflecting heightened market interest in these operational updates.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
QuidelOrtho Reports Q2 2026 Results and New IR Lead. QuidelOrtho released its second-quarter 2026 earnings, with reports noting that profit margins have recovered while cash levels remain a point of discussion. The company also announced the appointment of Sanjeev Sharma as Vice President of Investor Relations. These updates provide context for the stock's current position within its 52-week range.
Transaction History
| NEO | ▲ Buy | Option Exercise | 57,413 | $0 | 2/23/2025 | View on chart |
| NEO | ▼ Sell | Tax Withholding | 14,067 | $0 | 2/23/2025 | View on chart |
| PACB | ▲ Buy | Grant | 54,099 | $0 | 1/30/2025 | View on chart |
| NEO | ▼ Sell | Tax Withholding | 33,130 | $0 | 8/15/2024 | View on chart |
| NEO | ▲ Buy | Option Exercise | 48,063 | $0 | 5/11/2024 | View on chart |
| NEO | ▼ Sell | Tax Withholding | 18,913 | $281K | 5/11/2024 | View on chart |
| NEO | ▲ Buy | Option Exercise | 48,063 | $0 | 5/11/2024 | View on chart |
| QDEL | ▲ Buy | Grant | 2,248 | $0 | 6/6/2023 | View on chart |
| QDEL | ▼ Sell | Tax Withholding | 1,225 | $105K | 5/27/2023 | View on chart |
| NEO | ▲ Buy | Grant | 265,452 | $0 | 8/15/2022 | View on chart |
| NEO | ▲ Buy | Grant | 336,767 | $0 | 8/15/2022 | View on chart |
| QDEL | ▲ Buy | Grant | 34,554 | — | 5/27/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NeoGenomics Shares Drop 12% on CEO Transition News
NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.
NeoGenomics Shares Drop 12% on CEO Transition News. NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.